The closing price of Travere Therapeutics Inc (NASDAQ: TVTX) was $6.32 for the day, down -0.78% from the previous closing price of $6.37. On the day, 1175223 shares were traded.
Ratios:
Our analysis of TVTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.47. In the meantime, Its Debt-to-Equity ratio is 2.02 whereas as Long-Term Debt/Eq ratio is at 1.99.
On December 05, 2023, Citigroup Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $7 to $10.
On November 20, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $7.Citigroup initiated its Neutral rating on November 20, 2023, with a $7 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 11 ’24 when Cline Christopher R. sold 54 shares for $6.74 per share. The transaction valued at 364 led to the insider holds 70,849 shares of the business.
Dube Eric M sold 19,122 shares of TVTX for $166,435 on Feb 01 ’24. The CHIEF EXECUTIVE OFFICER now owns 350,600 shares after completing the transaction at $8.70 per share. On Feb 01 ’24, another insider, REED ELIZABETH E, who serves as the SVP, GC & CORPORATE SECRETARY of the company, sold 4,764 shares for $8.71 each. As a result, the insider received 41,495 and left with 76,270 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.42 while its Price-to-Book (P/B) ratio in mrq is 2.37.
Stock Price History:
Over the past 52 weeks, TVTX has reached a high of $22.75, while it has fallen to a 52-week low of $5.25.
Shares Statistics:
A total of 75.37M shares are outstanding, with a floating share count of 75.03M. Insiders hold about 1.41% of the company’s shares, while institutions hold 113.82% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by TG Therapeutics, Inc. analysts. The consensus estimate for the next quarter is $15.24, with high estimates of $6.32 and low estimates of $1.30.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
